Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.
CITATION STYLE
Wang, Y., Sanchez, L., Siegel, D. S., & Wang, M. L. (2016, July 15). Elotuzumab for the treatment of multiple myeloma. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-016-0284-z
Mendeley helps you to discover research relevant for your work.